This will be a phase 1/2, multicenter, open-label study using the oral formulation of IXAZOMIB administered twice weekly in combination with lenalidomide and low-dose dexamethasone. Both phases of the study will include patients who have newly diagnosed multiple myeloma and have not previously received systemic treatment.